Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors

Conclusions Nivolumab at doses of 1 –20 mg/kg was not associated with DLTs, and it was generally well tolerated at doses of up to 20 mg/kg in Japanese patients with advanced solid tumors.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research